Humana slides as GAAP EPS outlook trimmed despite solid Q1 benefit ratio
Humana shares fell after reporting Q1 2026 results that included Adjusted EPS of $10.31 and an Insurance benefit ratio of 89.4%. Investors focused on a cut to full-year 2026 GAAP EPS guidance to at least $8.36, while adjusted EPS guidance stayed at least $9.00.
1. What happened
Humana stock traded lower on Wednesday, April 29, 2026, after the company posted first-quarter 2026 results and updated its full-year outlook. Humana reported Q1 2026 GAAP EPS of $9.83 and Adjusted EPS of $10.31, and said its Insurance segment GAAP benefit ratio was 89.4%, slightly favorable to its outlook for just under 90%. (humana.gcs-web.com)
2. What investors are reacting to
Despite the solid quarter, Humana revised its full-year 2026 GAAP EPS guidance down to at least $8.36 from at least $8.89, while affirming its full-year 2026 Adjusted EPS guidance of at least $9.00. The company reiterated that the full-year outlook reflects a year-over-year decline tied to the Medicare Advantage Star Ratings headwind for Bonus Year 2026, net of mitigation. (humana.gcs-web.com)
3. Key operating read-throughs for the rest of 2026
Humana reaffirmed its expectation for approximately 25% individual Medicare Advantage membership growth in 2026, positioning growth as a key offset as the company works through the Star Ratings-driven earnings pressure. Humana also highlighted CenterWell expansion, including sequential growth of 110,500 patients in CenterWell Senior Primary Care and integration of the MaxHealth acquisition footprint, alongside growth in state-based contracts membership. (humana.gcs-web.com)
4. What to watch next
Investors will focus on whether Humana can hold its 2026 Insurance segment benefit ratio guidance at 92.75% plus or minus 25 basis points as membership grows, and whether any further GAAP guidance adjustments emerge as the year progresses. Management commentary on the earnings call is likely to center on Medicare Advantage bid season, medical-cost trend visibility, and execution in CenterWell and state-based contracts as catalysts for sentiment. (humana.gcs-web.com)